Monday, December 23, 2024
HomeTagsPRA023

PRA023

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Prometheus Biosciences, Inc. a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics